Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma
Open Access
- 1 January 1998
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 9 (1) , 37-43
- https://doi.org/10.1023/a:1008211909585
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancerAnnals of Oncology, 1997
- 507 A phase II study of taxol® (T) (paclitaxel) over 3 hours (H) in 192 platinum pretreated patients (PTS) for ovarian carcinoma (OC)European Journal Of Cancer, 1995
- Salvage Chemotherapy for Epithelial Ovarian CarcinomaGynecologic Oncology, 1994
- Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.Journal of Clinical Oncology, 1994
- Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.Journal of Clinical Oncology, 1992
- A multicenter phase II study of carboplatin in advanced ovarian carcinoma: Final reportAnnals of Oncology, 1992
- Long-term survival in ovarian cancerEuropean Journal of Cancer and Clinical Oncology, 1991
- Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.BMJ, 1991
- Carboplatin dosage: prospective evaluation of a simple formula based on renal function.Journal of Clinical Oncology, 1989
- Recurrent ovarian carcinoma: Retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agentGynecologic Oncology, 1985